Repligen Completes Expansion of U.S. Manufacturing Facility

mia.burns WALTHAM, MA – November 1, 2013 – Repligen Corporation today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham ...

Roche snags FDA nod for ‘breakthrough’ Rituxan successor

Damian Garde Just as biosimilar competition creeps up on blockbuster Rituxan, Roche and partner Biogen Idec have won FDA approval for the cancer drug's heir, marking the first success ...

Roche’s Rituxan successor first up in market scramble for first-line treatment of CLL

Eric Palmer A number of drugmakers have been looking to get drugs across the finish line for approval of first-line use in the treatment of chronic lymphocytic leukemia, and Roche's ...

Waiting Period for Omnicom and Publicis Ends

mia.burns Omnicom and Publicis Groupe Announce Expiration of Hart-Scott-Rodino Act Waiting Period NEW YORK and PARIS, Nov. 1, 2013 /PRNewswire/ — Omnicom Group Inc. (NYSE: OMC) ...

Merck whacking 500 at West Point, PA, plant

Eric Palmer For West Point, PA, Merck giveth and Merck taketh away. In the midst of significant downsizing, right now Merck is taking away 500 jobs from the extensive facility there. FiercePharma ...

Mylan Confirms First-to-File Patent Challenge Relating to Uloric

mia.burns -Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, Nov. 1, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today confirmed that its U.S.-based ...

Celladon swings for $92M in up-charged IPO

Damian Garde 2012 Fierce 15 member Celladon has boosted its IPO goals, seeking as much as $ 92 million to help get its gene therapy for heart failure through a Phase IIb study and ...

Once again, Bayer’s new drugs power pharma sales upward

Carly Helfand Eye drug Eylea and blood thinner Xarelto are pretty good products for any drugmaker to have in its lineup, and Bayer's got them both. Sales of those new stars have ...

And Now, One Of Our Favorite Halloween Tunes…

esilverman We are showing our age, but not ashamed to enjoy ourselves. Now, if only the Great Pumpkin would appear… Read more Pharmalive – The Pulse of the Pharmaceutical ...

GlobeImmune pulls plug on $75M IPO despite still-bubbling market

Damian Garde After repeated delays, Colorado immunotherapy developer GlobeImmune has finally called it quits on plans to raise up to $ 74.8 million in an IPO, citing poor market conditions ...

Vertex’s Incivek unseats Celebrex as fastest drug launch ever

Eric Palmer A new report starkly illustrates how quickly things can change in the pharma industry, showing how a drug darling becomes a market dud. FiercePharma News
Page 8 of 8« First...45678
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS